AU2015305401A1 - HIV antibody therapy as treatment substitute - Google Patents

HIV antibody therapy as treatment substitute Download PDF

Info

Publication number
AU2015305401A1
AU2015305401A1 AU2015305401A AU2015305401A AU2015305401A1 AU 2015305401 A1 AU2015305401 A1 AU 2015305401A1 AU 2015305401 A AU2015305401 A AU 2015305401A AU 2015305401 A AU2015305401 A AU 2015305401A AU 2015305401 A1 AU2015305401 A1 AU 2015305401A1
Authority
AU
Australia
Prior art keywords
hiv
pro
tnd
study
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015305401A
Other languages
English (en)
Inventor
Nader Z. POURHASSAN
Robert T. SCHOOLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytodyn Inc
Original Assignee
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodyn Inc filed Critical Cytodyn Inc
Publication of AU2015305401A1 publication Critical patent/AU2015305401A1/en
Priority to AU2021202132A priority Critical patent/AU2021202132A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015305401A 2014-08-20 2015-08-20 HIV antibody therapy as treatment substitute Abandoned AU2015305401A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021202132A AU2021202132A1 (en) 2014-08-20 2021-04-07 Hiv antibody therapy as treatment substitute

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462039620P 2014-08-20 2014-08-20
US62/039,620 2014-08-20
US201562192941P 2015-07-15 2015-07-15
US62/192,941 2015-07-15
PCT/US2015/046160 WO2016029049A1 (en) 2014-08-20 2015-08-20 Hiv antibody therapy as treatment substitute

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202132A Division AU2021202132A1 (en) 2014-08-20 2021-04-07 Hiv antibody therapy as treatment substitute

Publications (1)

Publication Number Publication Date
AU2015305401A1 true AU2015305401A1 (en) 2017-03-02

Family

ID=55351264

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015305401A Abandoned AU2015305401A1 (en) 2014-08-20 2015-08-20 HIV antibody therapy as treatment substitute
AU2021202132A Abandoned AU2021202132A1 (en) 2014-08-20 2021-04-07 Hiv antibody therapy as treatment substitute

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021202132A Abandoned AU2021202132A1 (en) 2014-08-20 2021-04-07 Hiv antibody therapy as treatment substitute

Country Status (11)

Country Link
US (2) US10562969B2 (https=)
EP (2) EP3904390A1 (https=)
JP (2) JP6767367B2 (https=)
KR (1) KR20170042706A (https=)
CN (1) CN106661113A (https=)
AU (2) AU2015305401A1 (https=)
BR (1) BR112017003252A2 (https=)
CA (1) CA2957817A1 (https=)
ES (1) ES2880950T3 (https=)
MX (1) MX2017002093A (https=)
WO (1) WO2016029049A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11584797B2 (en) 2015-06-23 2023-02-21 Cytodyn Inc. Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions
US20190085086A1 (en) * 2017-09-18 2019-03-21 Cytodyn Inc. Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy
WO2024008177A1 (en) * 2022-07-08 2024-01-11 Nanjing Curegene Technology Co., Ltd. Engineered cells and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
AU2004251228B2 (en) 2003-05-16 2008-04-24 University Of Maryland Biotechnology Institute Compositions for down-regulation of CCR5 expression and methods of use therefor
CN101495145A (zh) * 2005-07-22 2009-07-29 原基因药物有限公司 用于减少受hiv-1感染的患者中病毒负荷的方法
WO2008134076A1 (en) * 2007-04-30 2008-11-06 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
US10500274B2 (en) * 2008-04-30 2019-12-10 Cytodyn Inc. Methods for reducing viral load in HIV-1 infected patients
US9956165B2 (en) 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof

Also Published As

Publication number Publication date
EP3904390A1 (en) 2021-11-03
KR20170042706A (ko) 2017-04-19
MX2017002093A (es) 2017-05-25
EP3183270A1 (en) 2017-06-28
JP7035143B2 (ja) 2022-03-14
US20200385475A1 (en) 2020-12-10
JP2021004249A (ja) 2021-01-14
BR112017003252A2 (pt) 2017-11-28
CA2957817A1 (en) 2016-02-25
WO2016029049A1 (en) 2016-02-25
EP3183270A4 (en) 2018-01-17
CN106661113A (zh) 2017-05-10
EP3183270B1 (en) 2021-04-28
JP2017527613A (ja) 2017-09-21
AU2021202132A1 (en) 2021-05-06
US10562969B2 (en) 2020-02-18
US20170335002A1 (en) 2017-11-23
JP6767367B2 (ja) 2020-10-14
ES2880950T3 (es) 2021-11-26

Similar Documents

Publication Publication Date Title
Navarro-Millán et al. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor
AU2021202132A1 (en) Hiv antibody therapy as treatment substitute
EP1910573A2 (en) Methods for reducing viral load in hiv-1-infected patients
JP7663660B2 (ja) Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
de Miguel Buckley et al. New strategies of ARV: the road to simplification
US20220396630A1 (en) Type i interferon inhibition in systemic lupus erythematosus
US20100178290A1 (en) Methods for reducing viral load in HIV-1 infected patients
US20200306372A1 (en) Methods for reducing viral load in hiv-1 infected patients
US20190085086A1 (en) Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy
US20250059280A1 (en) Methods of treating human immunodeficiency virus (hiv) disease
HK40063361A (en) Hiv antibody therapy as treatment substitute
CA3070319C (en) Regimens for treating hiv infections and aids
Aladul et al. CP-024 Factors affecting uptake of biosimilars
Daood R. Daood, K. Toledano, D. Markovits, Y. Tavor, S. Giryes, K. Dolnikov, H. Jeffries, A. Balbir-Gurman, Y. Braun-Moscovici
WO2009014638A2 (en) Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1
WO2009134401A9 (en) Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1
Uppal Rheumatology reviews: Julye-September 2012

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted